Chimeric Proteins for Cell-Based Deubiquitinase Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying anti-deubiquitinase compounds, particularly targeting the human proteasomal Rpn11 deubiquitinase, face challenges such as poor in vitro activity, lack of target-specific cell-based assays, and failure to address cell permeability and acute cellular toxicity, making it difficult to develop effective anticancer therapies.
Innovation Solution
Development of chimeric proteins comprising a mammalian deubiquitinase catalytic domain, a linker domain, and a non-human deubiquitinase proteasome binding domain, which are used in cell-based assays to screen for compounds with deubiquitinase inhibition activity, allowing for high-throughput, cost-effective, and less equipment-dependent screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If biochemical screening methodologies are used to identify deubiquitinase inhibitors, then compound screening can be performed, but expensive reagents are required and critical parameters such as cell permeability and acute cellular toxicity cannot be assessed
Solution Approach 1:
The invention changes the assay system from in vitro biochemical assays to in vivo cell-based assays. This parameter change enables simultaneous assessment of compound efficacy, cell permeability, and cellular toxicity, while eliminating the need for expensive biochemical reagents. The cell-based system naturally incorporates all necessary physiological parameters.
Solution Approach 2:
The invention uses cell-based assays as an intermediary system that bridges the gap between simple biochemical screening and complex in vivo studies. The cell-based assay serves as a middle ground that provides physiologically relevant data including cell permeability and toxicity information without requiring expensive in vivo models or complex biochemical reagents.
2Productivity
If biochemical screening methodologies are used to identify deubiquitinase inhibitors, then compound screening can be performed, but cell permeability and acute cellular toxicity parameters cannot be addressed
Solution Approach 1:
The invention transitions from in vitro biochemical assays to in vivo cell-based assays, fundamentally changing the assessment parameters. This enables simultaneous measurement of compound efficacy, cell permeability, and acute cellular toxicity in a single assay system, providing comprehensive and reliable data for drug development.
3Reliability
If Rpn11 deubiquitinase is targeted for anticancer therapy, then therapeutic potential is achieved, but poor in vitro activity and lack of target-specific assays hinder inhibitor identification
Solution Approach 1:
The invention introduces cell-based assays as an intermediary system specifically for Rpn11 inhibitor screening. These assays overcome the limitations of in vitro biochemical assays by providing a physiologically relevant environment that enables efficient identification of potent and selective Rpn11 inhibitors with proper cellular penetration and toxicity profiles.
4Productivity
If current screening methods are used, then compound identification can proceed, but the process requires expensive reagents and specialized equipment
Solution Approach 1:
The invention replaces expensive, specialized biochemical assay systems with simpler, more accessible cell-based assay systems. The cell-based assays use readily available cell culture reagents and standard laboratory equipment, eliminating the need for expensive specialized instruments and complex biochemical preparations while maintaining high screening productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables cell-based analysis of deubiquitinase inhibition, specifically Rpn11, facilitating the identification of potent and selective anti-deubiquitinase compounds with potential anticancer activity, while reducing the need for expensive reagents and specialized equipment.
Implementation Method 1
Deubiquitinase proteins serve to catalytically hydrolyze ubiquitin moieties from ubiquitinated proteins
Data Source
AI summary
A chimeric protein having deubiquitinase activity, methods of identifying anti-deubiquitinase compounds using chimeric proteins, and kits comprising chimeric proteins are described herein. In one aspect, a chimeric protein comprises a mammalian deubiquitinase catalytic domain, a linker domain, and a non-human deubiquitinase proteasome binding domain. In another aspect, a method of identifying a compound having deubiquitinase inhibition activity comprises a) providing an assay for identifying a compound having deubiquitinase inhibition activity, wherein the assay comprises one or more biological cells comprising a chimeric protein comprising a mammalian deubiquitinase catalytic domain, a linker domain, and a non-human deubiquitinase proteasome binding domain; b) screening the assay with at least one compound; and c) identifying a compound having deubiquitinase inhibition activity based on survival of the biological cell. In another aspect, a kit comprises a biological cell comprising a herein disclosed chimeric protein.